Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • wilderguide wilderguide Feb 13, 2013 6:20 PM Flag

    NCT01708954: w &w/o erlotinib 2nd-3rd LOT NSCLC

    $$$$

    Recent (2/6/12) protocol changes to this trial make me think that perhaps the competitive/diagnostic/therapeutic landscape has forced some revisions. Changes in KRAS & EGFR recognitions have been added.
    What am I missing?

 
EXEL
4.20-0.03(-0.71%)Feb 11 4:00 PMEST